Dashboard
Manage Tickers

GMABGENMAB A/S

Nasdaq genmab.com


$ 27.78 $ 0.09 (0.31 %)    

Monday, 10-Jun-2024 12:12:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 464.61 $ 1.82 (0.39 %)
DIA $ 388.35 $ -0.14 (-0.04 %)
SPY $ 534.79 $ 1.54 (0.29 %)
TLT $ 90.89 $ -0.14 (-0.15 %)
GLD $ 213.56 $ 0.47 (0.22 %)
$ 27.77
$ 27.69
$ 0.00 x 0
$ 27.78 x 100
$ 27.65 - $ 27.81
$ 26.32 - $ 42.72
291,606
na
124.97M
$ 0.78
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

truist-securities-maintains-buy-on-genmab-raises-price-target-to-53
Truist Securities Maintains Buy on Genmab,...
06/04/2024 12:54:42

Truist Securities analyst Asthika Goonewardene maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $5...

genmabs-phase-2-trial-shows-tisotumab-vedotin-achieves-325-objective-response-rate-in-head-and-neck-cancer
Genmab's Phase 2 Trial Shows Tisotumab Ved...
06/03/2024 13:11:09

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
06/03/2024 10:34:22

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

reported-earlier-genmabs-epcoritamab-shows-95-response-rate-in-untreated-follicular-lymphoma-patients-in-preliminary-epcore-nhl-2-study-results
Reported Earlier, Genmab's Epcoritamab Sho...
06/03/2024 06:28:05

Preliminary analysis of data from the EPCORE™ NHL-2 study demonstrates patients with previously untreated follicular lymphoma...

Core News & Articles
Genmab, BioNTech Announced Data At ASCO, S...
06/02/2024 15:02:07

Genmab A/S (NASDAQ:GMAB) and BioNTech SE (NASDAQ:BNTX) todayannounced initial data from the Phase 2 GCT1046-04 trial (NCT051172...

intuit-workday-and-other-big-stocks-moving-lower-in-fridays-pre-market-session
Intuit, Workday And Other Big Stocks Movin...
05/24/2024 09:45:52

what-9-analyst-ratings-have-to-say-about-genmab
What 9 Analyst Ratings Have To Say About G...
05/20/2024 15:00:19

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
05/20/2024 10:26:42

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

genmab-announces-presentation-of-multiple-abstracts-on-epcoritamab-at-2024-european-hematology-association-congress-on-june-13-16
Genmab Announces Presentation Of Multiple ...
05/14/2024 14:10:14

genmab-announces-presentation-of-multiple-abstracts-on-epcoritamab-at-2024-european-hematology-association-congress-on-june-13-16-2024
Genmab Announces Presentation Of Multiple ...
05/14/2024 14:09:41

Core News & Articles
Watching Genmab; Shares Trading Higher Aft...
05/13/2024 16:00:50

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
05/03/2024 19:59:17

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

genmab-q1-2024-revenue-60425m
Genmab Q1 2024 Revenue $604.25M
05/02/2024 15:05:48

decoding-9-analyst-evaluations-for-genmab
Decoding 9 Analyst Evaluations For Genmab
04/30/2024 12:00:57

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
04/30/2024 10:22:57

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

Core News & Articles
FDA OKs Seagen's Tivdak (tisotumab vedotin...
04/29/2024 19:53:09

- Bloomberg

genmab-reports-darzalex-q1-net-sales-of-2692b
Genmab Reports DARZALEX Q1 Net Sales Of $2...
04/16/2024 10:42:24

profoundbio-discovers-the-joys-of-having-a-wealthy-owner
ProfoundBio Discovers The Joys Of Having A...
04/08/2024 15:43:57

Key Takeaways: Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion The d...

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
04/04/2024 15:26:23

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

genmab-to-acquire-profoundbio-for-18b-cash-enhancing-and-expanding-its-oncology-portfolio
Genmab To Acquire ProfoundBio For $1.8B Ca...
04/03/2024 05:42:07

Genmab to acquire ProfoundBio for USD 1.8 billion in cash Acquisition will give Genmab worldwide rights to three candidates in...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)